$14.79+0.09 (+0.61%)
At close: Nov 17, 2026, 4:00 PM ET· NYSE · USD
Dr. Reddy's Laboratories (RDY) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
Sources Company filings FilingsHow we compute thisNot investment advice
11 figures withheld by our checks. Each blank figure names its reason.
Business engineChoppy: revenue is 98% below its peak, net margin 12.6%; free cash flow runs at 44% of net income. Check the accrual gap.
The lines that matter · FY22–FY26
Revenue ($M)—
3,580.0
FY22→FY26CAGR −64.1%/yr
Net income ($M)—
452.0
FY22→FY26CAGR −62.8%/yr
Free cash flow ($M)—
197.0
FY22→FY26CAGR −61.6%/yr
What the receipts whisper · what a headline number hides
Share count
+0.3%
832.1mn → 834.7mn diluted shares since FY22. Broadly flat, so EPS moves with net income rather than with the share count.
What the income statement says · FY22–FY26
Where every revenue dollar goes · FY26 ($M)
13¢ of every revenue dollar becomes profit. The biggest cost lever is COGS.
Margin trend · direction beats level Gross Operating Net
Over this window: gross 53.1% → 52.8%. Net margin 12.6% is more than double the sector median.
The receipt · income statement · FY22–FY26 USD millions except per-share & ratios · hover a line for its definition
USD millions except per-share & ratios
| Line item | FY26 † | FY26 | FY25 | FY24 | FY23 | FY22 | YoY | CAGR 22→26 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | 3,580.0 | 3,580.0 | 0.0 | 0.0 | 0.0 | 214,391.0 | — | −64.1% |
Cost of revenue | 1,691.0 | 1,691.0 | 0.0 | 0.0 | 0.0 | 100,551.0 | — | −64.0% |
Gross profit | 1,889.0 | 1,889.0 | —A | —A | —A | 113,840.0 | — | — |
Research & development | 256.0 | 256.0 | 0.0 | 0.0 | 0.0 | 17,482.0 | — | −65.2% |
Selling, general & admin | 1,137.0 | 1,137.0 | 0.0 | 0.0 | 0.0 | 62,081.0 | — | −63.2% |
Total operating expenses | 1,350.0 | 1,350.0 | 0.0 | 0.0 | 0.0 | 84,364.0 | — | −64.4% |
Operating incomefeeds ROC rank | 539.0 | 539.0 | 0.0 | 0.0 | 0.0 | 29,476.0 | — | −63.2% |
Other income, net | 45.0 | 45.0 | 0.0 | 0.0 | 0.0 | 2,822.0 | — | — |
Pretax income | 584.0 | 584.0 | 0.0 | 0.0 | 0.0 | 32,298.0 | — | −63.3% |
Income tax | 132.0 | 132.0 | 0.0 | 0.0 | 0.0 | 8,730.0 | — | −64.9% |
Net incomePiotroski ROA ✓feeds Buffett Quality owner earnings | 452.0 | 452.0 | 0.0 | 0.0 | 0.0 | 23,568.0 | — | −62.8% |
| Per share | ||||||||
Diluted EPSbuyback-sensitive | — | —B | —B | —B | —B | —B | — | — |
Diluted shares (mn) | 834.66 | 834.66 | 834.46 | 834.09 | 832.64 | 832.13 | ▲0.0% | +0.1% |
| Margins | ||||||||
Gross margin31st pct in Healthcare | 52.8% | 52.8% | —A | —A | —A | 53.1% | — | — |
Operating margin | 15.1% | 15.1% | — | — | — | 13.7% | — | — |
Net margin73rd pct in Healthcare | 12.6% | 12.6% | — | — | — | 11.0% | — | — |
† FY26 = fiscal 2026, through 2026-03-31; the trailing year is not available.A Withheld: cost of revenue is not on file, so the gross margin is not measured.B Withheld by our checks.
5 more years of statements and CSV export are on Premium, and 6 more on Ultimate.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
These lines feed the tenet checklists: see which gates passTenets →Margins & returns continue as sector-ranked ratiosStatistics →
Annual report filed 2026-05-29 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Statements normalized in our fundamentals DB · Not investment advice.
Common questions
What was Dr. Reddy's Laboratories' net income?
Dr. Reddy's Laboratories reported net income of $452.0M in fiscal 2026, a net margin of 12.6%.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

